<li>amikacin<p>sirolimus will increase the level or effect of amikacin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>amiodarone<p>amiodarone will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>amitriptyline<p>sirolimus will increase the level or effect of amitriptyline by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>astragalus<p>sirolimus increases and astragalus decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>atorvastatin<p>atorvastatin will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>axitinib<p>sirolimus increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>azithromycin<p>sirolimus will increase the level or effect of azithromycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>bazedoxifene/conjugated estrogens<p>sirolimus will increase the level or effect of bazedoxifene/conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>belatacept<p>belatacept and sirolimus both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor.</p></li><li>benazepril<p>benazepril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>boceprevir<p>boceprevir increases levels of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Plasma concentrations of sirolimus are expected to be increased significantly during coadministration with boceprevir. Close monitoring of immunosuppressant blood levels is recommended.</p></li><li>bosutinib<p>bosutinib increases levels of sirolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>brodalumab<p>brodalumab, sirolimus. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, brodalumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of brodalumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>budesonide<p>sirolimus will increase the level or effect of budesonide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>captopril<p>captopril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>cholera vaccine<p>sirolimus decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clobetasone<p>sirolimus will increase the level or effect of clobetasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clotrimazole<p>clotrimazole will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>colchicine<p>sirolimus will increase the level or effect of colchicine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>conjugated estrogens<p>sirolimus will increase the level or effect of conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>conjugated estrogens, vaginal<p>sirolimus will increase the level or effect of conjugated estrogens, vaginal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cortisone<p>sirolimus will increase the level or effect of cortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>crizotinib<p>crizotinib increases levels of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of crizotinib with CYP3A substrates with narrow therapeutic indices should be avoided.<span><br><br></span>crizotinib increases levels of sirolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>crofelemer<p>crofelemer increases levels of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyclosporine<p>cyclosporine will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Simultaneous coadministration significantly increases sirolimus levels; this is minimized by administering sirolimus 4 hr after cyclosporine <span><br><br></span>cyclosporine will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Simultaneous coadministration significantly increases sirolimus levels; this is minimized by administering sirolimus 4 hr after cyclosporine<span><br><br></span>cyclosporine and sirolimus both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor.<span><br><br></span>sirolimus increases toxicity of cyclosporine by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Elevations in serum creatinine, hemolytic uremic syndrome, TTP, and microangiopathy were observed when sirolimus used in combination with full-dose cyclosporine; this effect is often reversible with cyclosporine dose reduction.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>deferasirox<p>deferasirox will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>deflazacort<p>sirolimus will increase the level or effect of deflazacort by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>denosumab<p>sirolimus, denosumab. Other (see comment). Use Caution/Monitor. 
Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.</p></li><li>dexamethasone<p>sirolimus will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dichlorphenamide<p>dichlorphenamide and sirolimus both decrease  serum potassium. Use Caution/Monitor.</p></li><li>digoxin<p>sirolimus will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>docetaxel<p>sirolimus will increase the level or effect of docetaxel by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dronabinol<p>dronabinol increases levels of sirolimus by plasma protein binding competition. Modify Therapy/Monitor Closely. Dronabinol is highly bound to plasma proteins and may displace and increase the free fraction of other concomitantly administered highly protein-bound drugs. This has not been confirmed in vivo. Caution with narrow therapeutic index drugs that are highly protein bound when initiating or increasing the dose of dronabinol.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for sirolimus toxicity and adjust dose as needed. <span><br><br></span>dronedarone will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. If given together, monitor for sirolimus toxicity and adjust dose as needed. </p></li><li>dulaglutide<p>dulaglutide, sirolimus. Other (see comment). Use Caution/Monitor. 
Comment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index.</p></li><li>dupilumab<p>dupilumab, sirolimus. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, dupilumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of dupilumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>echinacea<p>sirolimus increases and echinacea decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>eliglustat<p>eliglustat increases levels of sirolimus by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>eluxadoline<p>eluxadoline increases levels of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution when CYP3A substrates that have a narrow therapeutic index are coadministered with eluxadoline.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>enalapril<p>enalapril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>estradiol<p>sirolimus will increase the level or effect of estradiol by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>estrogens conjugated synthetic<p>sirolimus will increase the level or effect of estrogens conjugated synthetic by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>estropipate<p>sirolimus will increase the level or effect of estropipate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ethotoin<p>ethotoin will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>felodipine<p>felodipine will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>fingolimod<p>sirolimus increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .</p></li><li>flibanserin<p>flibanserin increases levels of sirolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Increase monitoring of concentrations of drugs transported by P-gp that have a narrow therapeutic index if coadministered with flibanserin.<span><br><br></span>sirolimus will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.</p></li><li>fludrocortisone<p>sirolimus will increase the level or effect of fludrocortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>fosinopril<p>fosinopril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>gentamicin<p>sirolimus will increase the level or effect of gentamicin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>glycerol phenylbutyrate<p>glycerol phenylbutyrate will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index.</p></li><li>hydrocortisone<p>sirolimus will increase the level or effect of hydrocortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>iloperidone<p>iloperidone increases levels of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>indinavir<p>indinavir will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>influenza virus vaccine quadrivalent, recombinant<p>sirolimus decreases effects of influenza virus vaccine quadrivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.</p></li><li>influenza virus vaccine trivalent, recombinant<p>sirolimus decreases effects of influenza virus vaccine trivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.</p></li><li>irinotecan liposomal<p>sirolimus will increase the level or effect of irinotecan liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ivermectin<p>sirolimus will increase the level or effect of ivermectin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ixekizumab<p>ixekizumab, sirolimus. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>kanamycin<p>sirolimus will increase the level or effect of kanamycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lapatinib<p>lapatinib will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lisinopril<p>lisinopril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>lomitapide<p>sirolimus increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.<span><br><br></span>lomitapide increases levels of sirolimus by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide.</p></li><li>loperamide<p>sirolimus will increase the level or effect of loperamide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>loratadine<p>loratadine will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lovastatin<p>lovastatin will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>maitake<p>sirolimus increases and maitake decreases immunosuppressive effects; risk of infection. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>maraviroc<p>sirolimus will increase the level or effect of maraviroc by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>meningococcal group b vaccine<p>sirolimus decreases effects of meningococcal group b vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine.</p></li><li>mercaptopurine<p>mercaptopurine and sirolimus both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor.</p></li><li>mestranol<p>sirolimus will increase the level or effect of mestranol by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>methotrexate<p>methotrexate and sirolimus both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Combination may increase risk of myelosuppression.</p></li><li>methylprednisolone<p>sirolimus will increase the level or effect of methylprednisolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>micafungin<p>micafungin increases levels of sirolimus by unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>midazolam<p>midazolam will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>mitotane<p>mitotane decreases levels of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>moexipril<p>moexipril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>mycophenolate<p>sirolimus will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nefazodone<p>nefazodone will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nelfinavir<p>sirolimus will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>neomycin po<p>sirolimus will increase the level or effect of neomycin po by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>netilmicin<p>sirolimus will increase the level or effect of netilmicin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nicardipine<p>nicardipine will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nifedipine<p>nifedipine will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nortriptyline<p>sirolimus will increase the level or effect of nortriptyline by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ocrelizumab<p>sirolimus and ocrelizumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration of ocrelizumab with high doses of corticosteroids is expected to increase the risk of immunosuppression.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>oritavancin<p>oritavancin will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Oritavancin is a weak CYP3A4 inducer; caution if coadministered with CYP3A4 substrates that have a narrow therapeutic index</p></li><li>osimertinib<p>osimertinib, sirolimus. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Osimertinib is a competitive inhibitor and inducer of CYP3A. Monitor sensitive CYP3A substrates for alterations in serum levels or efficacy/toxicity.</p></li><li>paclitaxel<p>sirolimus will increase the level or effect of paclitaxel by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>paclitaxel protein bound<p>sirolimus will increase the level or effect of paclitaxel protein bound by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>palbociclib<p>palbociclib will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The dose of  sensitive CYP3A substrates with a narrow therapeutic index may need to be reduced if coadministered with palbociclib</p></li><li>paliperidone<p>sirolimus will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>paromomycin<p>sirolimus will increase the level or effect of paromomycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>perindopril<p>perindopril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ponatinib<p>ponatinib increases levels of sirolimus by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely.</p></li><li>posaconazole<p>sirolimus will increase the level or effect of posaconazole by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>prednisolone<p>sirolimus will increase the level or effect of prednisolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>prednisone<p>sirolimus will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>quercetin<p>quercetin will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>quinapril<p>quinapril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>ramipril<p>ramipril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>ranolazine<p>ranolazine will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>reserpine<p>reserpine will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ribociclib<p>ribociclib will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution if ribociclib is coadministered with sensitive CYP3A4 substrates that have a narrow therapeutic index. Dose reduction for sensitive CYP3A4 substrates may be needed.</p></li><li>rifampin<p>rifampin will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>risperidone<p>sirolimus will increase the level or effect of risperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rolapitant<p>rolapitant will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor for adverse reactions when unable to avoid coadministration with narrow therapeutic index P-gp substrates.</p></li><li>saquinavir<p>sirolimus will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>secukinumab<p>secukinumab, sirolimus. Other (see comment). Use Caution/Monitor. 
Comment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, secukinumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of secukinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect.</p></li><li>silodosin<p>sirolimus will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>siltuximab<p>siltuximab, sirolimus. Other (see comment). Use Caution/Monitor. 
Comment: CYP450 activity in the liver is down regulated by infection and inflammation stimuli including cytokines (eg, IL-6); inhibition of IL-6 by siltuximab may restore CYP450 enzymatic activity; caution if coadministered with CYP substrates that have a narrow therapeutic index.</p></li><li>simeprevir<p>simeprevir, sirolimus. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration may result in mildly increased or decreased sirolimus plasma concentrations; routine monitoring of blood concentrations of sirolimus is acceptable.</p></li><li>simvastatin<p>simvastatin will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>sipuleucel-t<p>sirolimus decreases effects of sipuleucel-t by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.</p></li><li>sofosbuvir/velpatasvir<p>sofosbuvir/velpatasvir will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Velpatasvir inhibits P-gp. Closely monitor P-gp substrates, particularly those with a narrow therapeutic index. Modify dose if needed.<span><br><br></span>sofosbuvir/velpatasvir increases levels of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Velpatasvir inhibits CYP3A4. Caution if coadministered with drugs with narrow therapeutics indexes.</p></li><li>spironolactone<p>spironolactone will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>streptomycin<p>sirolimus will increase the level or effect of streptomycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>tacrolimus<p>sirolimus will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>teduglutide<p>teduglutide increases levels of sirolimus by Other (see comment). Use Caution/Monitor. 
Comment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.</p></li><li>telaprevir<p>telaprevir increases levels of sirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Plasma concentration of sirolimus may be increased when co-administered with telaprevir, though this has not been studied.  Significant dose reductions and prolongation of the dosing interval of the immunosuppressant to achieve the desired blood levels should be anticipated. Close monitoring of the immunosuppressant blood levels, and frequent assessments of renal function and immunosuppressant-related side effects are recommended when co-administered with telaprevir. .</p></li><li>telotristat ethyl<p>telotristat ethyl will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Telotristat ethyl induces CYP3A4 and may reduce systemic exposure of sensitive CYP3A4 substrates. Monitor for suboptimal efficacy and consider increasing the dose of the CYP3A4 substrate.</p></li><li>tenofovir df<p>sirolimus, tenofovir df.
Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Use Caution/Monitor.<span><br><br></span>sirolimus increases levels of tenofovir df by decreasing renal clearance. Use Caution/Monitor.</p></li><li>tipranavir<p>tipranavir, sirolimus. Other (see comment). Use Caution/Monitor. 
Comment: Sirolimus levels may incr or decr, due to contradictory effects of tipranavir on hepatic CYP3A4 and P glycoprotein.</p></li><li>tobramycin<p>sirolimus will increase the level or effect of tobramycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>tolvaptan<p>sirolimus will increase the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>tolvaptan will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>trandolapril<p>trandolapril, sirolimus.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Coadministration increases risk of angioedema.</p></li><li>trazodone<p>trazodone will decrease the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>triamcinolone<p>sirolimus will increase the level or effect of triamcinolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vemurafenib<p>vemurafenib increases levels of sirolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>verapamil<p>verapamil will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vinblastine<p>sirolimus will increase the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vincristine<p>sirolimus will increase the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vincristine liposomal<p>sirolimus will increase the level or effect of vincristine liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li>